$DOCS

Sitaram Siddharth sold $38K of DOCS

Sitaram Siddharth (Chief Accounting Officer) sold 1,732 shares of Doximity, Inc. (DOCS) at $22.02 on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sitaram Siddharth
Published Jul 20, 2026, 2:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 20, 2026, 2:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DOCS
Neutral
high confidence
Mentioned
$DOCS
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DOCSNeutralLow
01

Why it matters

This provides a concrete datapoint on insider ownership reduction by the CFO, but it does not introduce new fundamentals or guidance.

02

Market read

Traders may note the insider sale for sentiment/positioning, but the 10b5-1 framing reduces interpretive weight.

03

What to watch

The article does not state whether the sale was part of a larger series, nor does it provide option exercises or purchases that could offset net insider selling.

Relevance 2/10Novelty 4/10Timing: Filed 2026-07-20, disclosing the 2026-07-15 insider sale details.

Background

The article is an SEC Form 4 insider transaction disclosure for Doximity, Inc. (DOCS).

Company-level read

Ticker impact

$DOCSNeutralHigh confidence
Context

SEC Form 4 shows Doximity CFO Sitaram Siddharth sold 1,732 shares at $22.0200 on a 10b5-1 plan, totaling $38,138.64.

Expected impact

Likely minimal near-term impact; treat as low-signal unless paired with other disclosures.

Evidence & confidence

The filing is a pre-arranged 10b5-1 open-market sale, and the article provides no new operational, financial, or regulatory catalyst beyond the transaction details.

Market effects

No direct sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with internal caution; monitor for additional insider sales or changes in trading patterns.

Key entities

  • Doximity, Inc.

    Company whose insider transaction is disclosed via SEC Form 4.

  • Sitaram Siddharth

    Chief Accounting Officer who executed an open-market sale under a 10b5-1 plan.

Related articles

$DOCSMed

Why Doximity Stock Skyrocketed on Friday

Doximity (NYSE: DOCS) shares rose after CEO Jeff Tangney said early returns from the company’s AI investments are improving profitability. In fiscal 2027 Q1 ended June 30, revenue increased 7% to $156.6M, while adjusted EBITDA fell 6% to $74.8M. Tangney cited >25% QoQ AI prompt volume growth and 10x AI Scribe users, plus revenue exceeding 10x search costs.

$DOCSMedAI 8/10

Doximity Q1 Earnings Call Highlights

Doximity (NYSE:DOCS) reported Q1 results, citing its expert-verified drug reference and physician-reviewed AI tools. It said it has 165 live health-system AI clients, including Northwestern, Penn Medicine and Michigan. AI Search launched in late April; no Q1 revenue recognized, with most expected in fiscal Q3. Q1 revenue retention: 112% top 20, 107% overall. Q2 revenue forecast $170M-$171M; FY2027 outlook raised to $671M-$681M.

$DOCSHighAI 9/10

A Lesser-Known Stock Climbed More Than 100% In a Day After AI Surprise. Here’s Why.

Doximity (DXRX) shares jumped after the company reported fiscal Q1 2027 results and said its new AI search product is generating strong unit economics. CEO Jeffrey Tangney said revenue is over 10 times per search versus cost. Q1 revenue was $156.6M and adjusted EBITDA $74.8M. Full-year revenue guidance raised to $671M-$681M; short interest was about 17%, contributing to a short squeeze.

$DOCSMedAI 8/10

Why Doximity Stock Is Up 80%

Doximity (NYSE:DOCS) shares jumped about 80% after CEO Jeffrey Tangney said its new AI search tool generates over 10 times more revenue per search than it costs. The company reported Q revenue up 7% to $156.6M and adjusted EBITDA of $74.8M, and raised full-year revenue guidance to $671M-$681M. FactSet said 17% of tradable shares were short before the report.